To substantiate the finding on BAX in DUSP16-mediated cisplatin resistance, we treated various types of vector- and DUSP16-overexpressing cancer cells including NPC HK-1, CRC DLD-1, gastric cancer NUGC3, and breast cancer MDA-MB-231 cells with BAX inhibitor Peptide V5. This evidence concerns the gene BAX and nasopharyngeal carcinoma.